News
10-19-2010, 04:15 AM
TykerbTM (lapatinib ditosylate) has received Health Canada approval for use in combination with letrozole (an aromatase inhibitor) for the treatment of post-menopausal women with hormone receptor-positive (HR+) metastatic breast cancer, whose tumours overexpress the HER2 (ErbB2) receptor, and who are suitable for endocrine therapy...
More... (http://mnt.to/f/3Lpc)
More... (http://mnt.to/f/3Lpc)